Results 151 to 160 of about 193,741 (293)
Concomitant Robotic Pericardial Window and Mediastinal Tumour Biopsy Under Intraoperative Ultrasound Guidance. [PDF]
Fiorelli A +3 more
europepmc +1 more source
ABSTRACT Background Clinically significant CNS involvement by CLL/SLL is uncommon, diagnostically challenging, and has no established standard treatment. Case A 61‐year‐old man with previously untreated CLL/SLL was admitted in April 2023 to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, with rapidly
Wei Xie +4 more
wiley +1 more source
Lymphomas Diagnosed Primarily on Serous Effusion Cytology: Cytology Rises to the Challenge! [PDF]
Soni V +5 more
europepmc +1 more source
ABSTRACT Background The emergence of personalized therapy and molecular sequencing has significantly transformed the management of advanced non–small cell lung carcinoma (NSCLC). Supernatants obtained from fine needle aspiration (FNA) have been shown to be a reliable source of high‐quality nucleic acid for molecular testing.
Adeyinka Akinsanya +9 more
wiley +1 more source
Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant
Pediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
Matthew R. Schuelke +9 more
wiley +1 more source
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell +11 more
wiley +1 more source
Giant esophageal schwannoma mimicking a mediastinal tumor: a case report and review of the literature. [PDF]
Saito M +5 more
europepmc +1 more source
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko +31 more
wiley +1 more source
Safety of eribulin: A real-world study based on a pharmacovigilance database. [PDF]
Zhou Y +7 more
europepmc +1 more source

